Novocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13

The second generation device is less than half the weight and half the size of the first generation Optune System ST. HELIER, Jersey–(BUSINESS WIRE)–Before starting treatment with Optune in October 2015, Michael Olson, 39, of Beaumont, Texas, worried about how he’d incorporate the treatment into his life and practice as a dentist. It wasn’t long …

Novocure to Present at Upcoming Investor Conferences

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will present at three upcoming investor conferences in August and September. William Doyle, Novocure’s Executive Chairman, will present at the Wedbush PacGrow 2016 Healthcare Conference in New York on Tuesday, Aug. 16, at 8:35 a.m. EDT. Mike Ambrogi, Novocure’s Chief Operating Officer, will present at …

Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update

Three months ended June 30, ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today reported financial results for the quarter ended June 30, 2016, highlighting year-over-year growth in prescriptions, active patients and reported revenues. Second quarter 2016 highlights include:     Three months ended June 30, …

Novocure to Host Research and Development Day on Dec. 12, 2016

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the company will hold a research and development day for analysts and investors on Monday, Dec. 12, 2016, from 1 to 4 p.m. EST in New York City. During the event, we plan to provide analyses from completed clinical trials, including the full 695 patient dataset from …

NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma

Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has recommended Optune as a standard treatment option for newly diagnosed glioblastoma (GBM) in its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) …

Novocure Receives FDA Approval for Second Generation Optune System

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its premarket approval (PMA) supplement application for Novocure’s second generation Optune system. The new smaller, lighter Tumor Treating Fields (TTFields) delivery system is now available to glioblastoma (GBM) patients in the United States. Novocure designed the second generation …

Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors

Non-dilutive financing enhances financial strength ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it has provided notice to draw the remaining $75 million under its existing term loan agreement with an investment fund managed by Pharmakon Advisors LP and anticipates receiving funds on July 22, 2016. Novocure drew $25 million of the total $100 …

Novocure to Report Second Quarter 2016 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2016 on Thursday, July 28, 2016 at 6:30 a.m. EDT before the open of U.S.-based financial markets. Novocure management will host a conference call and webcast to discuss its second quarter 2016 financial results at 8 a.m. …

Novocure to Present at JMP Securities 2016 Life Sciences Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Mike Ambrogi, Novocure’s Chief Operating Officer, will present at the JMP Securities 2016 Life Sciences Conference in New York. Mr. Ambrogi will present on Wednesday, June 22nd at 11:30 a.m. EDT. A live audio webcast of the presentation will be available on Novocure’s website. The audio …

Novocure Receives IDE Approval to Initiate METIS Trial

Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the United States Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the METIS trial. METIS is a …